Press Releases :: OPKO Health, Inc. (OPK)

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Read the news release

Visit BioReference Health

Year

Category

Aug 5, 2015 4:00 pm EDT

OPKO Announces Second Quarter Operating and Financial Results

Aug 5, 2015 1:18 pm EDT

Two Reports on hGH-CTP Pediatric Phase 2 Clinical Data Accepted for Oral Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE conference)

Jul 30, 2015 4:35 pm EDT

OPKO To Announce Second Quarter Operating and Financial Results on August 5, 2015

Jul 28, 2015 1:41 pm EDT

FDA Accepts OPKO’s New Drug Application for Rayaldee™

Jul 10, 2015 9:25 am EDT

OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient Adults

Jul 10, 2015 9:00 am EDT

OPKO Investee SciVac Announces the Completion of Transaction with Levon Resources

Jul 2, 2015 11:10 am EDT

OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned Acquisition

Jul 1, 2015 8:57 am EDT

Conversion Right Extended on OPKO 3.0% Convertible Senior Notes

Jun 26, 2015 10:25 am EDT

OPKO 4Kscore® Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection

Jun 9, 2015 11:54 am EDT

OPKO to Present New Data at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress on Its Long-Acting Clotting Factor VIIa